ONCAlert | Upfront Therapy for mRCC
Lymphomas: Articles
Expert Discusses Combinations, Other Research for the Treatment of Indolent Lymphomas
3:50 PM, Wed June 26, 2019
Relapsed/Refractory PMBCL Shows High Response Rate to Nivolumab and Brentuximab Vedotin
4:01 PM, Mon June 24, 2019
Sophisticated Risk Assessment and Prophylactic Strategies Needed for CNS Relapse in DLBCL
2:38 PM, Wed June 19, 2019
Polatuzumab Vedotin Combo Approved by FDA for R/R DLBCL
4:58 PM, Mon June 10, 2019
A Look Back at FDA News from May 2019
3:34 PM, Fri May 31, 2019
Copanlisib Given FDA Breakthrough Designation for Marginal Zone Lymphoma
6:52 PM, Thu May 30, 2019
Expert Highlights Early Efficacy Seen With Mosunetuzumab in Follicular Lymphoma and DLBCL
7:48 PM, Wed February 27, 2019
Fowler Highlights Trials Accruing at MD Anderson for Relapsed/Refractory Follicular Lymphoma
7:15 PM, Wed February 27, 2019
